Ancient Neanderthal Genetic Variant Tied to Reduced Schizophrenia Risk and Smaller Brain Region

A specific segment of Neanderthal DNA found in modern humans is associated with a nearly 10 percent lower risk of developing schizophrenia, according to a study published in Proceedings of the National Academy of Sciences USA. The genetic variant correlates with a reduction in the size of the occipital lobe, a brain region involved in visual processing, by about 0.85 cubic centimeters per copy carried. The findings are based on data from the UK Biobank and were analyzed by researchers at the University of California, San Francisco.
A 2026 study published in the Proceedings of the National Academy of Sciences USA reveals that a specific Neanderthal-derived genetic variant present in modern humans is associated with a nearly 10 percent reduced risk of schizophrenia. The research, led by scientists at the University of California, San Francisco, analyzed data from the UK Biobank and found that each copy of the variant correlates with a reduction of approximately 0.85 cubic centimeters in the volume of the occipital lobe—a brain region critical for visual processing. Individuals carrying two copies experienced a total reduction of about 1.7 cubic centimeters. The variant is located near the DAAM1 gene, which plays a role in early brain development, though its precise mechanism remains unclear. Despite Neanderthals historically having larger occipital lobes than modern humans, this genetic legacy appears to reduce the size of the same region in contemporary carriers. The study’s findings are notable because the variant was not linked to other psychiatric conditions such as depression, bipolar disorder, or ADHD, nor was it associated with intelligence. Co-authors Svante Pääbo of the Max Planck Institute for Evolutionary Anthropology and Hugo Zeberg of the Karolinska Institute emphasize that most Neanderthal DNA in modern humans likely originated from a single interbreeding event around 47,000 years ago. The team plans to continue searching for other functional Neanderthal genetic segments.
This discovery could influence psychiatric genetics and personalized medicine by highlighting how ancient human ancestry may modulate disease risk through subtle neuroanatomical changes. While the effect size is small—10 percent reduction in schizophrenia risk—the finding adds to growing evidence that archaic DNA contributes meaningfully to modern human health, potentially informing future genetic screening or therapeutic strategies. The lack of association with other mental health conditions suggests a highly specific biological pathway, which may help isolate mechanisms underlying schizophrenia without confounding factors. A comparable precedent is the discovery of Neanderthal-derived immune-related genes that influence responses to infections like COVID-19, showing how ancient variants can have lasting, measurable impacts on modern populations. However, it remains unknown whether this variant affects cognitive performance or behavior beyond brain structure. The broader implications for neuroscience and evolutionary medicine are still unfolding. Researchers may soon identify additional Neanderthal-derived sequences with clinical relevance, especially as genomic databases expand. What’s next could include functional studies in model organisms to test DAAM1 interactions or population-level analyses across diverse ancestries to assess whether the protective effect is consistent globally.